Opinion
Video
Safety Profile of Available Frontline Treatments LR-MDS
Author(s):
Key opinion leaders evaluate the safety profiles of available frontline treatments for patients with lower-risk myelodysplastic syndromes, including observed adverse reactions.
- Briefly comment on the safety profile of available frontline treatments for patients with LR-MDS.
- How would you mitigate those events in your practice?
- How does toxicities observedimpact your overall treatment selection for patients?
Related Videos
Related Content
